ATE68698T1 - D-cycloserin und deren prodrugs zur verbesserung kognitiver faehigkeiten. - Google Patents

D-cycloserin und deren prodrugs zur verbesserung kognitiver faehigkeiten.

Info

Publication number
ATE68698T1
ATE68698T1 AT88119863T AT88119863T ATE68698T1 AT E68698 T1 ATE68698 T1 AT E68698T1 AT 88119863 T AT88119863 T AT 88119863T AT 88119863 T AT88119863 T AT 88119863T AT E68698 T1 ATE68698 T1 AT E68698T1
Authority
AT
Austria
Prior art keywords
cycloserin
prodrugs
improving cognitive
cognitive skills
skills
Prior art date
Application number
AT88119863T
Other languages
German (de)
English (en)
Inventor
Alex A Cordi
Gail E Handelmann
Joseph B Monahan
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Application granted granted Critical
Publication of ATE68698T1 publication Critical patent/ATE68698T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT88119863T 1987-12-01 1988-11-29 D-cycloserin und deren prodrugs zur verbesserung kognitiver faehigkeiten. ATE68698T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/127,121 US4904681A (en) 1987-12-01 1987-12-01 D-cycloserine and its prodrugs as cognitive enhancers
EP88119863A EP0319824B1 (en) 1987-12-01 1988-11-29 D-cycloserine and its prodrugs as cognitive enhancers

Publications (1)

Publication Number Publication Date
ATE68698T1 true ATE68698T1 (de) 1991-11-15

Family

ID=22428413

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88119863T ATE68698T1 (de) 1987-12-01 1988-11-29 D-cycloserin und deren prodrugs zur verbesserung kognitiver faehigkeiten.

Country Status (20)

Country Link
US (1) US4904681A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP0319824B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JPH0621065B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR0134198B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE68698T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (4) AU622630B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1328617C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3865817D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK173589B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2040314T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI885559A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3003571T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE61825B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL88531A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO885337D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ227131A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH26467A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT89109B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1989005144A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA888981B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187171A (en) * 1989-01-09 1993-02-16 G. D. Searle & Co. Use of a glycine b partial agonist as an antipsychotic
US5061721A (en) * 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5260324A (en) * 1990-02-06 1993-11-09 G. D. Searle & Company Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5066665A (en) * 1990-05-21 1991-11-19 Warner-Lambert Co. Substituted isoxazolidin-3-ones and derivatives thereof acting at muscarinic receptors
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア ルイザ Nmda受容体のアロステリックモジュレーター
US5428069A (en) * 1993-01-11 1995-06-27 The United States Of America As Represented By The Department Of Health & Human Services Treating cognition with, aminocyclopropanecarboxylic derivatives
US5523323A (en) * 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
NZ260302A (en) * 1994-04-13 1996-05-28 New Zealand Meat Ind Res Inst Treating bait aversion by including substances which disrupt the associative learning process into bait compositions
AU4019395A (en) * 1994-11-23 1996-06-17 G.D. Searle & Co. Use of amino-isoxazolidone compounds for improvement of implicit memory
AU4128896A (en) * 1994-11-23 1996-06-17 G.D. Searle & Co. Use of amino-isoxazolidone compounds for treatment of memory impairment following traumatic brain injury
DE69614835T2 (de) * 1995-02-15 2002-04-25 Annovis, Inc. Alkylcarboxy-aminosäure modulatoren für den kainat-rezeptor
ES2260773T3 (es) * 1995-12-07 2006-11-01 Daniel C. Javitt Tratamiento de los sintomas negativos y cognitivos de la esquizofreniacon antagonistas de la absorcion de glicina.
US6361957B1 (en) * 1999-08-03 2002-03-26 Glytech, Inc. Assay for D-serine transport antagonist and use for treating psychosis
US6355681B2 (en) * 1995-12-07 2002-03-12 Glytech, Inc. Glycine substitutes and precursors for treating a psychosis
FR2742748B1 (fr) * 1995-12-21 1998-01-30 Adir Nouveau derive de 4-imidazolidinone, son procede de preparation et les compositions pharmaceutiques qui le contiennent
KR100396114B1 (ko) * 1996-10-31 2003-11-20 동아제약 주식회사 D-시클로세린의 제조방법
EP2338482A3 (en) 1998-04-14 2011-12-21 The General Hospital Corporation Methods for treating neuropsychiatric disorders
US7067545B1 (en) 1998-06-10 2006-06-27 Meiji Seika Kaisha Ltd. Remedies for spinocerebellar ataxia and compositions for treating spinocerebellar ataxia
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US7750030B2 (en) * 2001-03-29 2010-07-06 Michael Davis Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
US20060252761A1 (en) * 2001-03-29 2006-11-09 Michael Davis Augmentation of extinction via administration of sub-antimicrobial doses of D-cycloserine
EP1389181A4 (en) * 2001-04-02 2005-10-19 Panorama Res Inc ANTIOXIDANT NITROXIDES AND NITRONES AS THERAPEUTIC AGENTS
US7160913B2 (en) * 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
UA80055C2 (en) * 2003-05-27 2007-08-10 Forest Laboratories Combination of nmda-receptor antagonist and selective inhibitor of serotonin reuptake for a depression and other pscihiatric disorders treatment
WO2005014797A2 (en) * 2003-08-08 2005-02-17 The Burnham Institute P16 mediated regulation of nmda receptors
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
RU2007140348A (ru) 2005-04-06 2009-05-20 Адамас Фармасьютикалс, Инк. (Us) Способы и композиции для лечения заболеваний цнс
WO2010033757A1 (en) 2008-09-18 2010-03-25 Naurex, Inc. Nmda receptor modulators and uses thereof
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 2차 구조 안정화된 nmda 수용체 조절제 및 그의 용도
BR112012020142A2 (pt) 2010-02-11 2020-08-18 Northwestern University moduladores do receptor de nmda com estrutura secundária estabilizada e usos dos mesmos.
JP6531042B2 (ja) 2013-01-29 2019-06-12 アプティニックス インコーポレイテッド スピロラクタム系nmda受容体モジュレーターおよびその使用
JP2016506961A (ja) 2013-01-29 2016-03-07 ノーレックス, インコーポレイテッドNaurex, Inc. スピロラクタム系nmda受容体モジュレーターおよびその使用
KR20150110784A (ko) 2013-01-29 2015-10-02 노렉스, 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
BR112015018087B1 (pt) 2013-01-29 2022-09-20 Aptinyx Inc Compostos moduladores de receptor n-metil-d-aspartato (nmda) de espiro-lactama, composição farmacêutica e uso dos mesmos
EA031905B1 (ru) 2013-01-29 2019-03-29 Аптиникс Инк. Спиролактамные модуляторы рецептора nmda и их применение
CN109415372B (zh) 2016-05-19 2021-01-15 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
SG11201900554YA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda modulators and methods of using same
ES2973283T3 (es) 2016-08-01 2024-06-19 Tenacia Biotechnology Hong Kong Co Ltd Moduladores de receptores de NMDA espirolactámicos y usos de los mismos
CN109937204B (zh) 2016-08-01 2022-11-25 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
ES2972533T3 (es) 2016-08-01 2024-06-13 Tenacia Biotechnology Hong Kong Co Ltd Moduladores del receptor de NMDA a base de espirolactama, y sus usos
KR102462288B1 (ko) 2016-08-01 2022-11-01 앱티닉스 인크. 스피로-락탐 및 비스-스피로-락탐 nmda 수용체 조정제 및 그의 용도
EP3427729A1 (en) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid for use in treating epileptic diseases, disorders or conditions
BR112020015710A2 (pt) 2018-01-31 2020-12-08 Aptinyx Inc. Moduladores de espiro-lactamas de receptores nmda e usos dos mesmos
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3050800C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1979-03-22 1989-06-22 Continental Pharma Inc., Bruessel/Bruxelles, Be

Also Published As

Publication number Publication date
FI885559A0 (fi) 1988-11-30
CA1328617C (en) 1994-04-19
GR3003571T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-03-16
PH26467A (en) 1992-07-27
AU1083992A (en) 1992-05-07
AU7746794A (en) 1995-01-05
NO885337D0 (no) 1988-11-30
IE61825B1 (en) 1994-11-30
EP0319824A1 (en) 1989-06-14
DK173589B1 (da) 2001-04-02
JPH05201859A (ja) 1993-08-10
JPH0621065B2 (ja) 1994-03-23
EP0421997A1 (en) 1991-04-17
AU622630B2 (en) 1992-04-16
EP0319824B1 (en) 1991-10-23
JPH01193220A (ja) 1989-08-03
IL88531A (en) 1993-02-21
KR890009392A (ko) 1989-08-01
KR0134198B1 (ko) 1998-04-21
NZ227131A (en) 1991-09-25
US4904681A (en) 1990-02-27
AU2813089A (en) 1989-07-05
IE883567L (en) 1989-06-01
ES2040314T3 (es) 1995-04-01
DK669088D0 (da) 1988-11-30
PT89109B (pt) 1993-07-30
AU2631988A (en) 1989-06-01
WO1989005144A1 (en) 1989-06-15
DK669088A (da) 1989-06-02
DE3865817D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1991-11-28
IL88531A0 (en) 1989-06-30
PT89109A (pt) 1989-12-29
ZA888981B (en) 1990-01-31

Similar Documents

Publication Publication Date Title
ATE68698T1 (de) D-cycloserin und deren prodrugs zur verbesserung kognitiver faehigkeiten.
DE3779053D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR1000023B (el) Καρβαμικος φαινυλεστηρ.
DE69307800D1 (de) Reaktionssystem zur Herstellung von mikrozellularen Elastomeren
FI945442A0 (fi) Uudet 7beta-substituoidut 4-atsa-5alfa-kolestanonit 5alfa-reduktaasi-inhibiittoreina
ATE43834T1 (de) Antimikrobiell wirksame substanzen, ihre herstellung und ihre verwendung.
FI945626A0 (fi) Menetelmä 2,2-difluoriketeenisilyyliasetaalien ja alfa, alfa-difluori-beta-silyylioksi-1,3-dioksolaani-4-propaanihappoestereiden valmistamiseksi
DE3872063D1 (de) Zusammensetzung mit anregender wirkung fuer die haare.
PT97259A (pt) Processo para a estabilizacao de isotiazolonas com fenoxialcanois
TR28583A (tr) Arilpirrol insektisidal ve akarisidal unsurlarin suspansiyon konsantrat terkipleri.
ES2042726T3 (es) Beta-alquilmelatoninas.
ATE180831T1 (de) L-gulono-gamma-lacton dehydrogenase
GB8714005D0 (en) Organic compounds
IE791378L (en) Alpha-difluoromethyl amino acids
DE3588208D1 (de) Cephalosporinderivative
GR80337B (en) L-arginine isoxicamate
DE3660426D1 (de) Urea acryl derivatives
FR2621212B1 (fr) Perfectionnement aux roues de plombage des semoirs
ES2108165T3 (es) Compuestos policiclicos 31668p y 31668u, un procedimiento para su produccion y su uso como agentes antibioticos o antitumorales.
AU538026B2 (en) Nitrile sulfenyl carbamates
ATA459777A (de) Holzbearbeitungsmaschine zur herstellung von kantholz od.dgl. olz od. dgl. olz od. dgl.
FR2627937B2 (fr) Perfectionnement aux roues de plombage des semoirs
ATE78828T1 (de) Verfahren und zwischenverbindungen fuer n-(s-3alkyl-heptanoyl)-d-gamma-glutamyl-glycyl-dalanine.
ATE69137T1 (de) Stabilisiertes gossyplure und verfahren zu dessen herstellung.
ATE3847T1 (de) Verfahren zur herstellung sauerstoffhaltiger kohlenstoffverbindungen.

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee